| abstract |
Provided are liquid formulations comprising high concentrations humanized antibodies for treating an IL-6-related disease. In some embodiments, the liquid formulation comprises 120-300 mg/mL of the antibody, 5-30 mM of a histidine salt buffer or 5-30 mM sodium acetate buffer, 0.1-1.0 mg/mL surfactant, 70-200 mM stabilizer and water for injection without antioxidant. The antibody formulation provides good antibody stability, acceptable viscosity for subcutaneous injection, prevents aggregation and degradation of the monoclonal antibody, and acidic isomer increase. The preparation is applicable in stabilizing the structure and function of the humanized antibody. |